Market data not licensed for redistribution.

Keeps Biopharma

256940 · KOSDAQ · Pharmaceuticals Manufacturing

– Previous close pending (official data.go.kr feed not active yet) Live price ↗

Source: Financial Services Commission stock price data (data.go.kr), updated once a day.

Daily price, 1 year

Key statistics

Market cap (KRW bn)–

PER–

PBR–

ROE %-16.5

Debt ratio % (liabilities / equity)194

Revenue TTM (KRW bn)220.5

Op. profit TTM (KRW bn)-0.6

Dividend yield %–

Basis: market cap at …; equity = total equity (consolidated if available) at 2026.06.30; net income = trailing 12 months to 2026.06.30 (consolidated). PER is not shown when TTM net income is negative.

Upcoming risk events

Next 90 days for this company, plus macro events tagged with this ticker or its sector. Not a recommendation.

No scheduled risk events found (last checked 2026-10-30 19:40 KST).

See it in the full calendar →

Annual results (KRW bn)

	2021	2022	2023	2024	2025
Revenue	4.3	14.6	92.1	127.6	170.1
Operating profit	-12.3	-8.6	3.1	6.2	1.6
Net income	-16.2	-12.0	3.5	1.6	-10.4

Quarterly results (KRW bn, 3 months)

	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Revenue	40.6	43.3	40.9	45.2	59.4	74.9
Operating profit	0.1	-1.0	1.4	1.0	-0.7	-2.4
Net income	-1.4	0.7	-0.4	-9.2	5.7	-9.0

Largest shareholder

As of the 2025 annual report: ㈜둠밈 and related parties hold 24.05% of common shares.

Recent disclosures

Date	Filing
2026-10-23	Insider / major-holder ownership report 주식등의대량보유상황보고서(일반)	DART original
2026-10-16	Insider / major-holder ownership report 임원ㆍ주요주주특정증권등소유상황보고서	DART original
2026-09-11	Clinical trial / regulatory approval 투자판단관련주요경영사항(임상시험계획승인신청등결정) (Idtrexed(CT900) 기반 항암 치료제의 제2상 임상시험계획(IND) 승인)	DART original
2026-08-18	Other 파생상품거래손실발생	DART original
2026-08-14	Periodic report (annual/half/quarterly) 반기보고서 (2026.06)	DART original
2026-07-24	Insider / major-holder ownership report 주식등의대량보유상황보고서(일반)	DART original
2026-07-06	Convertible bond issuance [기재정정]주요사항보고서(전환사채권발행결정)	DART original
2026-06-02	IR event 기업설명회(IR)개최	DART original
2026-05-15	Periodic report (annual/half/quarterly) 분기보고서 (2026.03)	DART original
2026-05-14	Insider / major-holder ownership report 임원ㆍ주요주주특정증권등소유상황보고서	DART original
2026-05-14	Insider / major-holder ownership report 주식등의대량보유상황보고서(일반)	DART original
2026-03-31	Governance / misc. (routine) 본점소재지변경	DART original

Past material filings and price reaction (market-adjusted)

Date	Filing type	On the news (vs. market)	Next day (vs. market)	20 days (vs. market)
2026-09-11	Clinical trial / regulatory approval	+7.2%	+1.3%	+7.5%
2026-03-13	Revenue/profit change >=30% (15% large caps)	+2.0%	-1.8%	+4.7%
2026-03-10	Clinical trial / regulatory approval	-0.3%	+2.8%	+5.9%
2026-02-11	Other material event (investment-relevant)	+2.0%	-4.9%	-11.6%
2025-10-24	Tangible asset / business transfer	-1.5%	+0.5%	+3.0%
2025-09-02	Tangible asset / business transfer	+0.4%	+4.4%	-14.0%
2025-06-16	Convertible bond issuance	+0.8%	+16.8%	-5.0%
2025-04-09	Disposal of shares in another company	-0.1%	-1.3%	+16.2%
2025-03-31	Other material event (investment-relevant)	-1.3%	+1.2%	+4.1%
2025-03-13	Revenue/profit change >=30% (15% large caps)	-0.9%	-2.0%	+16.1%

For information only, not investment advice. Data may be delayed or inaccurate. Full disclaimer → Data: OpenDART (FSS), stock prices: official previous-day close from the Financial Services Commission (data.go.kr) and FinanceData/marcap history, index data via FinanceDataReader, FX: ECB reference rates, crypto data from Upbit, Bithumb and Binance public APIs.
Market data not licensed for redistribution.
© Crypvu · Crypto market view